Summit Therapeutics (NASDAQ:SMMT) Upgraded by Zacks Investment Research to Hold

Summit Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Summit Therapeutics Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Strong Sell.

Shares of Summit Therapeutics traded up $0.09 on Wednesday, reaching $5.36. 0 shares of the stock traded hands, compared to its average volume of 211554. Shares of Summit Therapeutics were trading at $5.36 on Wednesday. The firm’s 50 day moving average is $6.64 and its 200 day moving average is $6.63.Summit Therapeutics has a 12 month low of $5.22 and a 12 month high of $12.30. While on yearly highs and lows, Summit Therapeutics’s today has traded high as $5.48 and has touched $5.22 on the downward trend. See More Analyst Rating at: RATING

Summit Therapeutics Earnings and What to expect: 

Summit Therapeutics last announced its quarterly earnings results on August 11th, 2021. The reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by $0.09. The business earned $6.18 million during the quarter, compared to analysts’ expectations of $4.45 million. Summit Therapeutics has generated ($0.75) earnings per share over the last year (($0.92) diluted earnings per share). Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($1.06) to ($1.07) per share. Summit Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 15th, 2021 based off prior year’s report dates.

Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($1.06) to ($1.07) per share. The P/E ratio of Summit Therapeutics is -5.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Summit Therapeutics is -5.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Summit Therapeutics has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Summit Therapeutics (NASDAQ:SMMT) Moving Average Technical Analysis

5 day Moving Average is $5.16 And 5 day price change is $0.46 (9.39%)  with average volume for 5 day average is 89,220. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $5.38 and 20 day price change is -$1.08 (-16.77%) and average 20 day moving volume is 229,965. 50 day moving average is $6.64  and 50 day price change is -$2.61 ( -32.75%)  and with average volume for 50 days is : 178,066. 200 day moving average is $6.63  and 200 day price change is $0.15 (2.88%)  and with average volume for 200 days is : 219,102.

Other owners latest trading in Summit Therapeutics :

  • On 8/23/2021 shares held by Morgan Stanley were 217,537 which equates to market value of $1.62M and appx 0.00% owners of Summit Therapeutics
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 53,165 which equates to market value of $0.40M and appx 0.00% owners of Summit Therapeutics
  • On 8/17/2021 shares held by Invesco Ltd. were 16,139 which equates to market value of $0.12M and appx 0.00% owners of Summit Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 11.39% for Summit Therapeutics

See More Analyst Rating at: RATING